|
Week’s Top
Deals Total Up to $2.6B |
Galderma
is acquiring CollaGenex
for approximately $420 million. CollaGenex is developing a product
for the treatment of rosacea-associated erythema, as well as a
product with the potential to provide added benefits for the
treatment of psoriasis. Galderma
(2/26)
Cypress
Bioscience is acquiring Proprius
Pharmaceuticals for $37.5 million upfront as well as an
additional $37.5 million in potential milestone-related payments
associated with the development of Proprius’ therapeutic
candidates. Proprius has a portfolio of proprietary personalized
medicine laboratory services and therapeutic product candidates. Cypress
Bioscience (2/25)
Genmab
is acquiring PDL BioPharma’s
antibody manufacturing facility for $240 million. Genmab expects the
facility will be sufficient to provide a sustainable source of both
clinical and commercial-scale material for its pipeline. Genmab
(2/21)
Acceleron
Pharma and Celgene
Corporation are collaborating on the joint development and
commercialization of ACE-011, a bone-forming compound, and have also
signed an option agreement for certain discovery stage programs.
Acceleron could receive up to $1.9 billion under the agreement. Acceleron
Pharma (2/20)
|
